Company Overview

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of hematology and hematology-oncology and allergy, dermatology, and rheumatology.

The leading prescription products are GRAFAPEX and Trecondyv, indicated in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT); IXINITY, for control & prevention of bleeding episodes & for perioperative management of patients with Hemophilia B; Rasuvo and Metoject, unique formulations of methotrexate (auto-injector and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases and Rupall, an innovative allergy medication with a unique mode of action.

Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares
Nov 20 2025, 7:30 AM EST

Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares
Nov 17 2025, 8:30 AM EST

Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Nov 12 2025, 6:06 PM EST

Management Team

Ken d'Entremont
Chief Executive Officer and Director

Brendon Buschman
Chief Financial Officer

Ian C Wildgoose Brown
General Counsel

Richard Labelle
Chief Operating Officer

Medexus Pharmaceuticals, Inc.
10 King Street East, Suite 600
Toronto, ON M5C 1C3
Canada